Schedule 13G ownership disclosure

Neurogene Inc

Common Stock, $0.000001 par value · CUSIP: 64135M105

Event date: 2024-12-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Redmile Group, LLC

    Shares: 1,479,766.00 · Class: 9.9%

  • Jeremy C. Green

    Shares: 1,479,766.00 · Class: 9.9%

  • Redmile Biopharma Investments I, L.P.

    Shares: 812,033.00 · Class: 5.4%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001104659-25-014381
Form type
SCHEDULE 13G/A
Filer
Neurogene Inc.
CIK
CIK 1404644
Filed
Feb 14, 2025
Reporting period
Dec 31, 2024
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub